Combined XXXX extraction and intravitreal bevacizumab in eyes with choroidal neovascularization resulting from age-related @entity1020 .

@entity1 @entity231 @entity2295 @entity2790 @entity1020 @entity3457
PURPOSE: To evaluate the safety and efficacy of phacoemulsification, @entity2790 ( @entity2790 ) implantation, and a single intravitreal injection of bevacizumab in @entity1 with coexisting visually significant @entity231 and @entity2295 due to age-related @entity1020 . SETTING: Department of Ophthalmology, University of Bari, Bari, Italy. METHODS: Eyes with predominantly @entity2295 and @entity231 had phacoemulsification, @entity2790 implantation, and a 1.25 mg intravitreal injection of bevacizumab. One month after combined surgery, corrected distance visual acuity (CDVA), anterior chamber reaction, and intraocular pressure were evaluated and central foveal thickness was measured by optical coherence tomography. RESULTS: Twenty eyes of 20 @entity1 were evaluated. One month postoperatively, the mean CDVA improved significantly, from 20/100 (range 20/160 to 20/80) at baseline to 20/63 (range 20/125 to 20/50) (P<.0001). The mean central foveal thickness decreased significantly, from 353.75 microm +/- 12.50 (SD) (range 334 to 375 microm) at baseline to 275.7 +/- 17.3 microm (range 255 to 323 microm) at 1 month (P<.0001). Intraocular pressure did not change significantly, and anterior chamber reaction was absent. No ocular or systemic adverse events were observed. CONCLUSION: Combined phacoemulsification, @entity2790 implantation, and intravitreal bevacizumab was a safe and efficacious treatment in @entity1 with visually significant @entity231 and @entity3457 .
